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Cellular effects of imatinib on
medullary thyroid cancer cells
harboring multiple endocrine neoplasia
Type 2A and 2B associated RET
mutations
J. W. B. de Groot, MD,a,d I. Plaza Menacho, MSc,b H. Schepers, MSc,c L. J. Drenth-Diephuis,c
J. Osinga,b J. Th. M. Plukker, MD, PhD,a Th. P. Links, MD, PhD,d B. J. L. Eggen, PhD,c and
R. M. W. Hofstra, PhD,b Groningen, The Netherlands
Background. Activating mutations in the RET gene, which encodes a tyrosine kinase receptor, often
cause medullary thyroid carcinoma (MTC). Surgical resection is the only curative treatment; no
effective systemic treatment is available. We evaluated imatinib, a tyrosine kinase inhibitor currently
used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug
for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia–
associated mutant RET receptors.
Methods. We determined RET expression and Y1062 phosphorylation using Western blot analysis and
quantitative polymerase chain reaction. We determined the effects on cell proliferation by a 3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide assay, and we used fluorescence-activated cell sorter analysis with annexin
V/propidium iodide staining to study imatinib-induced cell-cycle arrest, apoptosis, and cell death.
Results. Imatinib inhibited RET Y1062 phosphorylation in a dose-dependent manner after 1.5 hours of
exposure. After 16 hours both RET Y1062 phosphorylation and protein expression levels were affected. Dose-
dependent decreases in cell proliferation of both cell lines after exposure to imatinib with inhibitory
concentration of 50% levels of 23  2 mol/L and 25  4 mol/L were seen. These values are high,
compared with those for chronic myelogenous leukemia and gastrointestinal stromal tumors. We further
could show that imatinib induced cell-cycle arrest, and apoptotic and nonapoptotic cell death.
Conclusions. Imatinib inhibits RET-mediated MTC cell growth affecting RET protein levels in vitro in
a dose-dependent manner. The concentration of imatinib necessary to inhibit RET in vitro, however,
makes it impossible to conclude that imatinib monotherapy will be a good option for systemic therapy of
MTC. (Surgery 2006;139:806-14.)
From the Departments of Surgical Oncology,a Medical Genetics,b Endocrinology,d University Medical Center
Groningen, Department of Developmental Genetics,c University of GroningenSurgery is, at this moment, the only adequate
curative intended treatment in medullary thyroid
carcinoma (MTC) consisting of a total thyroidec-
tomy with at least a central compartment dissec-
tion.1,2 Clearance of all neoplastic tissue in the
neck may improve disease-free survival with nor-
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806 SURGERYmalization of calcitonin levels. Unfortunately, more
than 50% of the patients will have persistent or
recurrent disease after initial surgery and are prone
to developing distant metastases for which there is
no adequate systemic treatment available.3–6 The
clinical presentation of MTC depends on the pres-
ence of specific mutations in the RET gene (REar-
ranged during Transfection), located on 10q11.
The RET gene encodes a receptor tyrosine kinase
with an extracellular ligand–binding domain and a
cysteine-rich domain, a single transmembrane do-
main, and an intracellular domain containing the
catalytic tyrosine kinase domain.7 Oncogenic acti-
vation of receptor tyrosine kinases can occur by
chromosomal translocation (as found in papillary
Surgery de Groot et al 807
Volume 139, Number 6thyroid carcinomas) and by single-point mutations.
Mutations in the extracellular cysteine–rich do-
main of the RET protein are encountered in
patients having the cancer syndrome multiple en-
docrine neoplasia type 2A (MEN 2A) and familial
MTC (FMTC), while mutations in the tyrosine ki-
nase domain are found in patients with FMTC and
MEN 2B.8–10 In MEN 2A, the most frequently
found mutation is C634R, whereas in MEN 2B, the
most frequently observed activating mutation in
RET is M918T.10 This mutation also is found in
approximately 40% of sporadic MTC cases.10,11
These mutations and translocations lead to ligand-
independent RET autophosphorylation, resulting
in a constitutively active RET receptor. In the he-
reditary form of MTC, RET mutations always are
observed, and RET expression is characteristic for
both the sporadic and hereditary type of MTC.
Small molecule drugs that can inhibit tyrosine
kinases selectively have proven to be useful in the
systemic treatment of a number of neoplastic dis-
eases. Recently the selective tyrosine kinase inhibi-
tor 571 (STI571, imatinib, Glivec, Gleevec,
CGP57148B; Novartis Pharma, Basel, Switzerland)
has been developed. It belongs to the 2-phe-
nylaminopyrimidine class and is proven to target
BCR-ABL, platelet derived growth factor receptor
(PDGFR)12,13 and c-kit receptor tyrosine ki-
nases.14,15 Currently, imatinib is used clinically to
treat chronic myelogenous leukemia (CML) and
gastrointestinal stromal tumors as well as dermato-
fibrosarcoma protuberans.16–21
Because both c-kit and RET belong to the same
subfamily of tyrosine kinase receptors, we investi-
gated whether RET tyrosine kinase (RET-TK) can
be inhibited by imatinib as well. Dose-dependent
growth inhibition induced by imatinib in the
human MTC cell line TT has been reported.22
However, others could not reproduce these data.23
Furthermore, it remains unclear whether the anti-
proliferative effect of imatinib is caused by inhibi-
tion of RET autophosphorylation or by induction
of apoptosis, or through other mechanisms; several
questions have been raised concerning the rela-
tively high concentrations of imatinib used.23,24 In
addition, only 1 MTC-derived cell line has been
used in previous studies.
Aims of this study were (1) to investigate
whether imatinib can inhibit the activity of onco-
genic RET mutants in vitro at clinical achievable
serum levels; (2) to determine whether imatinib
induces growth arrest and/or cell death in 2 MTC
cell lines: TT, a cell line reported to be derived
from a sporadic MTC carrying a C634W RET mu-
tation,25,26 and MZ-CRC-1, a cell line derived froma malignant pleural effusion from a patient with
metastatic sporadic MTC carrying a M918T muta-
tion26,27; and (3) to determine whether there is
specificity of imatinib for particular RET mutations
associated with MEN 2A and MEN 2B.
MATERIAL AND METHODS
The human MTC cell line MZ-CRC-1 was a gift
of A. Knuth; the human MTC cell line TT and the
human hepatocellular carcinoma cell line HepG2
were obtained from the American Type Culture
Collection (Manassas, Va). RPMI 1640 medium,
Dulbecco modified Eagle medium (DMEM), tryp-
sin-EDTA, L-glutamine, and penicillin-streptomy-
cin were purchased from Gibco (Invitrogen Corp,
Breda, The Netherlands) and fetal calf serum
(FCS) from Integro BV (Zaandam, The Nether-
lands). Antibodies against RET (H300), PY-RET
(Y1062) and actin (C4) were used in dilutions of
1:1000, 1:250, and 1:10000, respectively. Antirabbit
IgG-HRPO peroxidase-conjugated antibodies were
used in dilutions of 1:2000. All antibodies were
purchased from Santa Cruz Biotechnology Inc
(Santa Cruz, Calif), except antiactin, which was
obtained from ICN Biomedicals (Aurora, Ohio).
Imatinib kindly was provided by Novartis Pharma
AG (Basel, Switzerland) and dissolved in dimethyl
sulfoxide (DMSO). MG132 was purchased from
Calbiochem (Merck Biosciences, Nottingham, UK)
and dissolved in DMSO.
Cell culture. MZ-CRC-1 cells were cultured in
DMEM supplemented with 10% (v/v) FCS, 100
U/mL penicillin, 100 g/mL streptomycin, and 2
mmol/L L-glutamine. TT cells were cultured in
RPMI 1640 supplemented with 15% (v/v) FCS, 100
U/mL penicillin, and 100 g/mL streptomycin.
HepG2 cells were maintained in DMEM supple-
mented with 10% (v/v) FCS, 100 U/mL penicillin,
and 100 g/mL streptomycin. Cells were main-
tained under a fully humidified atmosphere of 95%
air and 5% CO2 at 37°C.
Western blot analysis. MZ-CRC-1 cells and TT
cells were grown at a density of 5  105 cells/well
for 48 hours and treated with different concentra-
tions of imatinib for 90 minutes. Cells were washed
with ice-cold phosphate-buffered saline (PBS) and
lysed with 100 L of lysis buffer (20 mmol/L
HEPES at pH 7.4, 2 mmol/L EGTA, 1 mmol/L
DTT, 1 mmol/L Na2VO3 (ortho), 1% Triton
X-100, 10% glycerol, 10 g/mL leupeptin, 30
g/mL aprotinin, and 0.4 mmol/L PMSF). Protein
concentration was determined according to the
Bradford method before SDS-polyacrylamide gel
electrophoresis.28 Forty micrograms of total cell
lysates were analyzed by Western blotting. Cell ly-
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mmol/L TRIS-Cl at pH 6.8, 20% glycerol, 0.01%
bromphenol blue, and 10% 2-mercaptoethanol)
before loading. Then they were separated on 12%
SDS-polyacrylamide gels and electroblotted in
TRIS-glycine buffer (39 mmol/L glycine, 48
mmol/L TRIS-Cl, 0.037% SDS, 20% methanol)
onto 0.20 mol/L nitrocellulose membranes (Bio-
Rad Labs, Hercules, Calif).
Membranes were incubated in blocking solution
(5% nonfat milk in TBS-T [25 mmol/L TRIS-Cl at
pH 8.0, 137 mmol/L NaCl, 5 mmol/L KCl, 0.05%
Tween]) for 1 hour at 22°C, followed by incubation
with anti-RET (H300), anti-PY-RET (Y1062), or an-
tiactin (C4) in fresh blocking solution at 4°C over-
night. The membranes were then washed in TBS-T
and incubated with a 1:2000 dilution of the indi-
cated HRPO-conjugated secondary antibody for 2
hours at 22°C. Membranes were then washed with
TBS-T. Antibody detection was performed with an
enhanced chemiluminescence reaction (Pierce
Chemical Co, Rockford, Ill) according to the man-
ufacturer’s recommendations.
RNA extraction, preparation of complementary
DNA and quantitative polymerase chain reaction.
TT cells were cultured for 24 hours in RPMI 1640
supplemented with 10% FCS, and subsequently
treated with or without 15 mol/L imatinib for 16
hours. Total RNA was isolated with the use of the
RNeasy Mini Kit (Qiagen GmBH, Hilden, Ger-
many) according to the manufacturer’s protocol.
The RNA concentration was determined by spec-
trophotometry (Nanadrop). Thereafter, 1 g of
total RNA was transcribed in first-strand comple-
mentary DNA (cDNA) with the use of the RTG First
Strand cDNA kit (Amersham Biosciences,’s-Herto-
genbosch, The Netherlands) according to the man-
ufacturer’s protocol. The cDNA synthesis was
primed by the pd(N)6 Random Hexamer (Amer-
sham). Relative changes in transcript level were
determined on the Icycler (Bio-Rad) with the use
of the Quantitect SYBR Green PCR Kit (Qiagen)
according to the manufacturer’s instructions.
Primer sequences used in this study were
as follows: hypoxanthine phosphoribosyl-
transferase (HPRT)-forward: cgcccaaagggaactgat-




gaagaa; RET-reverse: tactccacgatgaggaggagc. The
polymerase chain reaction (PCR) efficiencies for
all primers used were between 96% and 99%. Data
are expressed as fold-induction corrected forGAPDH and HPRT. All experiments were per-
formed in duplicate.
Proliferation assay. To determine cell prolifera-
tion, we used a 3-[4,5-dimethylthiazol-2-yl]-2,5-di-
phenyltetrazolium bromide (MTT) assay (Roche
Diagnostics, Almere, The Netherlands). Briefly,
cells were seeded at a density of 1  105 cells/well
in 96-well microtiter plates, grown overnight, and
exposed to different concentrations of imatinib or
0.1% DMSO as a control. After 1, 2, 3, 4, and 5 days
of incubation, respectively, 10 L of MTT reagent
was added to each well, and the plate was incubated
at 37°C for 4 hours. Formazan products were solu-
bilized with 100 L/well of the supplied detergent
buffer, and the plate was incubated overnight at
37°C. The optical density was determined at 595
nm wavelength. To determine the inhibitory
concentration of 50% (IC50) of imatinib (the con-
centration that causes 50% growth inhibition), a
concentration range of imatinib was added to the
wells (quadruplicates), and IC50 was determined by
using linear interpolation at r  0.5. All experi-
ments were performed in triplicate.
Cell cycle and apoptosis analysis. For fluores-
cence-activated cell sorting (FACS) analysis, cells
were cultured subconfluent and treated with 15
mol/L imatinib for 24, 48, 72, and 96 hours. The
percentage of apoptotic cells was assessed with the
use of an annexin V staining kit (IQ Products,
Groningen, The Netherlands) according to the
manufacturer’s recommendations. Briefly, cells
were harvested, resuspended in 100 L calcium
buffer (2.6 mg/mL HEPES, 0.28 mg/mL CaCl2,
8.18 mg/mL NaCl) containing 5 L annexin V,
and incubated for 20 minutes at 4°C in the dark.
Cells were washed with 5 mL calcium buffer and
subsequently incubated in 300 L calcium buffer
containing 2.5 L propidium iodide (PI) for 10
minutes in the dark. Finally, binding of fluorescein-
conjugated annexin V (apoptotic death) and PI
(necrotic death) was measured by FACS (FACSCali-
bur; Becton Dickinson, Sunnyvale, Calif). For as-
sessing cell-cycle distribution, cells were harvested,
washed with PBS, and incubated in PI solution (0.1
g/L Rnase A, 0.96 mg/mL sodium citrate-dihy-
drate, 0.02 g/L PI, 0.1 % Triton X-100) for 20
minutes at room temperature. Binding of PI was
measured by FACS, and cell-cycle analysis was per-
formed with the use of ModFit LT.
Statistical analysis. Values shown are depicted as
mean  SD. The relationship between continuous
variables was analyzed with the use of the Student t
test. In all tests, P  .05 was considered significant.
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Imatinib inhibits RET autophosphorylation in
MZ-CRC-1 and TT cells in a dose-dependent
manner. Lysates prepared from MZ-CRC-1 and TT
cells treated with imatinib for 90 minutes were
analyzed by Western blotting with an anti-PY-RET
(Y1062) antibody. Inhibition of RET Y1062 auto-
phosphorylation was observed in a dose-dependent
manner, with complete inhibition observed at con-
centrations higher than 15 mol/L in both cell
lines (Fig 1).
To exclude that the observed reduction in RET
Y1062-phosphorylation was caused by decreased
RET-protein levels, we striped and reprobed the
membrane with an anti-RET primary antibody. The
total amount of expressed RET did not change
after exposure to imatinib for 90 minutes indicat-
ing that imatinib inhibits RET autophosphoryla-
tion but does not affect the expression level of the
RET protein (Fig 1).
Long-term exposure to imatinib induces RET
oncoprotein levels. To investigate the effects of ex-
tended exposures to imatinib on RET expression and
phosphorylation levels in MZ-CRC-1 and TT cells, we
prepared cell lysates after 16 hours of exposure to
imatinib and analyzed them by Western blotting.
Complete inhibition of RET Y1062 autophosphoryla-
tion was observed at concentrations higher than 10
mol/L in both cell lines (Fig 2). Reprobing the
membrane with an anti-RET antibody showed that
RET expression levels also were reduced by long-term
imatinib treatment, indicating that reduced RET
Y1062 phosphorylation levels are caused by reduced
RET protein levels. In MZ-CRC-1 cells, expression
levels of RET protein decreased dramatically, and, in
TT cells, RET could not be detected at concentra-
tions of 15 and 20 mol/L (Fig 2). To determine
whether equal amounts of protein were loaded, the
Fig 1. Dose-dependent inhibition of RET autophosphor-
ylation in MZ-CRC-1 and TT cells after 90 minutes expo-
sure. MZ-CRC-1 cells and TT cells were grown at a density
of 5  105 cells/well for 48 hours and treated with
different concentrations of imatinib for 90 minutes.
Forty micrograms of total cell lysates were Western blot-
ted; the blots were probed with anti-PY-RET (Y1062),
stripped, and probed with anti-RET.blots were stripped and reprobed with an antiactinantibody, and the total amount of actin did not
change after exposure to imatinib.
We used the proteasome inhibitor MG132 to
determine if RET was degraded by the protea-
some-ubiquitin pathway under the influence of
imatinib by adding 10 mol/L MG132 to MZ-
CRC-1 and TT cells in combination with increas-
ing concentrations of imatinib. Cells were treated
for 16 hours and whole-cell lysates were Western
blotted and developed with an anti-RET anti-
body. In both cell lines, RET protein levels were
still reduced by imatinib (Fig 3). MG132 did not
have any influence on RET protein levels, and
transcription was not altered by imatinib.
Therefore, we studied the effects of imatinib
on RET gene expression by means of quantitative
PCR (qPCR; Fig 4). Treatment of TT cells with 15
mol/L imatinib for 16 hours did not result in a
decreased synthesis at the transcription level.
Therefore, we conclude that imatinib does not
decrease RET protein levels by enhancing pro-
tein degradation through the proteasome-ubiq-
uitin pathway or inhibition of RET gene
transcription.
Imatinib inhibits proliferation of MZ-CRC-1 and
TT cells. The effect of imatinib on cell growth of
MTC-derived cell lines was measured by means of
an MTT assay. MZ-CRC-1 and TT cells were incu-
bated with increasing concentrations of imatinib
for up to 5 days (Fig 5). To determine the IC50 of
imatinib in MTC cell lines, MZ-CRC-1 and TT cells
were grown in normal FCS-containing medium and
exposed to increasing concentrations of imatinib
(Fig 6). The concentrations of imatinib required
Fig 2. Imatinib inhibits both autophosphorylation and
protein levels of RET in MZ-CRC-1 and TT cells after 16
hours exposure. MZ-CRC-1 and TT cells were grown at a
density of 5  105 cells/well for 48 hours and treated
with different concentrations of imatinib for 16 hours.
Forty micrograms of total cell lysates were Western blot-
ted; the blots were probed with anti-PY-RET (Y1062),
stripped, and probed with anti-RET. Loading controls
were done by stripping the blot again and probing for
actin.inhibiting cell growth by 50% were 23  2 mol/L
810 de Groot et al Surgery
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cells.
Imatinib promotes cell cycle arrest and
apoptosis. We evaluated the contribution of cyto-
toxic and cytostatic components to imatinib-in-
duced growth inhibition. First, simultaneous
annexin V/PI staining was employed to determine
whether cell death occurred and to clarify the na-
ture of cell death in the treated cultures. FACS
cell-cycle analysis showed that treatment with ima-
tinib increased apoptotic cell death after 3 days of
treatment (Fig 7, A). The fraction of apoptotic
cells, however, is relatively small. Second, we deter-
mined the distribution over the different cell-cycle
phases of MZ-CRC-1 cells treated with imatinib. For
these experiments, only MZ-CRC-1 cells were used,
as they proved to be diploid (data not shown) in
Fig 3. Imatinib treatment does not induce proteasomal
RET degradation. MZ-CRC-1 and TT cells were grown at
a density of 5  105 cells/well for 48 hours and treated
with different concentrations of imatinib and 10 mol/L
of the proteasome inhibitor MG132 for 16 hours. Forty
micrograms of total cell lysates were Western blotted; the
blots were probed with anti-RET, stripped, and probed





















Fig 4. Long-term treatment with imatinib does not de-
crease RET expression levels. TT cells were grown in
RPMI 15% FCS for 48 hours and subsequently treated
with 15 mol/L imatinib or only RPMI 15% FCS for 16
hours. RET mRNA was quantified by quantitative PCR.
Data are expressed as fold-induction corrected for hypo-
xanthine phosphoribosyltransferase (HPRT) and glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) and ob-
tained from 2 independent experiments.contrast to TT cells, which were described asaneuploid (http://www.biotech.ist.unige.it/cldb/
totcl4901.html). As shown in Figure 7, B, imatinib
treatment increased the percentage of MZ-CRC-1
cells in the G0/G1-phase of the cell cycle. This
increase of cells in the G0/G1-phase is accompa-
nied by a reduced number of cells in the S-phase,
supporting the observations obtained with the
MTT assay. The analysis did reveal considerable
significant (P  .001 for increase in S-phase; P 
.003 for changes in G0/G1-phase) changes in the
cell-cycle distribution pattern after 24 hours of in-
cubation, compared with untreated cells. In con-
clusion, these data show that the main mechanism
of imatinib-induced growth inhibition in vitro is
through cell-cycle arrest in the G0/G1-phase, al-
though induction of apoptosis plays a (small) role
as well.
DISCUSSION
The increasing knowledge of the critical signal-
ing pathways responsible for the growth of malig-
nancies has lead to the development of specific
inhibitors of these pathways as new tools in cancer
therapy. Treatment of patients with CML, gastroin-
testinal stromal tumor, and dermatofibrosarcoma
protuberans with imatinib is an example of the
positive clinical effects of the increasing knowledge
of cancer-specific signal transduction inhibition
and the use of specific signal transduction inhibi-
tors.16–21
A tumor for which no systemic treatment is yet
available is MTC. MTC is a malignancy caused by
mutations in the RET gene, which result in a con-
stitutive active receptor tyrosine kinase (RET-TK).
Recent reports have demonstrated that inhibition
of constitutive active RET-TK has cytostatic or cyto-
toxic effects on MTC cells.22,29–32 As the tyrosine
kinase domain of RET shows high homology with
that of the tyrosine kinases, which can be inhibited
by imatinib, we tested the effects of imatinib on
RET.
Our analyses demonstrate that imatinib indeed
has a dose-dependent inhibitory effect on cell pro-
liferation of both MZ-CRC-1 and TT cell lines, the
only 2 available MTC cell lines. In addition, ima-
tinib does inhibit RET specifically, since RET Y1062
autophosphorylation of both cell lines is inhibited
selectively after 90 minutes of exposure to imatinib,
whereas RET protein levels are not affected. As
reduction of phosphorylation of RET was seen in
both cell lines, imatinib seems not to be selective
for the particular RET mutations present in these
cell lines (C634W and M918T).
Skinner et al23 recently reported no significant
inhibition of TT cell proliferation at 10 mol/L of
erime
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MZ-CRC-1 and TT cells is inhibited by 10 mol/L
of imatinib; similar results were obtained by Cohen
et al.22 These discrepancies possibly are caused by
differences in experimental procedures employed
by the different research groups. Another possibil-
ity could be that imatinib is not as effective after
more than 5 days and that the effect is reversible.
We observed that, in concentrations higher than 20
mol/L, MZ-CRC-1 and TT cells stop proliferating.
This phenomenon also was observed in cell lines
that are not dependent on constitutive tyrosine
kinase activity, such as HepG2. Probably imatinib’s
effects on cell growth are due to general cytotoxic-
ity.
Although we proved that RET is a direct target
of imatinib, we also have reason to believe that this
inhibitor has other targets in TT and MZ-CRC-1.
This conclusion is based on observed clear differ-
ences in the concentration necessary to inhibit
RET phosphorylation, compared with the concen-
tration needed to inhibit cell proliferation. The
concentration of imatinib that decreased autophos-
phorylation and RET content was more than 10
and 15 mol/L, respectively. However, cell prolif-
Fig 5. Imatinib inhibits proliferation of MZ-CRC-1 and
seeded in DMEM 10% FCS (A) and TT cells were see
phosphoribosyltransferase 5  105 cells/well and treated
seeded in DMEM 10% FCS (C) in a density of 5000 cell
measured on subsequent days by 3-(4, 5-methylthiazol-
presented here are representative of 3 independent experation was already inhibited with 1 and 5 mol/Limatinib. This difference suggests that cell prolifer-
ation in MTC probably is not entirely dependent
on RET-TK activity, implying that imatinib acts on
other cellular pathways as well.
When MTC cells are exposed to imatinib for a
longer period, not only reduced Y1062 phosphor-
ylation but also reduced levels of RET protein were
observed. This might indicate that the observed
reduction in Y1062-phosphorylation after 16 hours
of treatment is a consequence of reduced RET
expression levels. The studies we performed with
the proteasome inhibitor MG132 show that RET
protein is not subjected to proteasomal degrada-
tion. Carniti et al32 demonstrated that PP1 inhibi-
tors induce degradation of RET oncoproteins
through proteasomal targeting. Imatinib, however,
induces RET degradation through other means.
Another possible mechanism for this loss of RET
could be a diminished RET expression. We, how-
ever, could show by qPCR that the expression was
not altered after 16 hours of treatment with ima-
tinib. The mechanism by which the inhibition of
RET phosphorylation could give rise to such a dras-
tic effect on RET expression levels is, therefore, yet
lls in a dose-dependent manner. MZ-CRC-1 cells were
n RPMI 15% FCS (B) at a density of 1 hypoxanthine
different concentrations of imatinib. HepG2 cells were
and served as a negative control. Cell proliferation was
, 5-diphenyl-tetrazolium bromide (MTT) assay. Results




2-yl)-2unknown. Possible explanations for the reduced
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June 2006RET expression are interference at translation level
or increased proteolysis of the RET protein.
The main mechanism of imatinib-induced
growth inhibition is that of cell-cycle arrest. In cell-
cycle analysis, we observed that imatinib induced a
change in the distribution of cells over different
cell-cycle phases, primarily a G0/G1 arrest (Fig 7,
B). Induction of apoptosis plays a (small) role as
well. It should be noted that the population of
MZ-CRC-1 and TT cells decreases after 5 days of
exposure to imatinib (data not shown). It could be
that nonapoptotic pathways play a role in cell death
as well, since only about 9% of cells were apoptotic
after 4 days of treatment with imatinib. It should be
noted that, in these experiments, cells have been
used that grow in culture for many years. It is
possible that primary MTCs respond differently to
imatinib.
The proliferation data show dose-dependent in-
hibition of cell growth by imatinib with IC50 of 23
2 and 25  4 mol/L in MZ-CRC-1 and TT cells,
































































Fig 6. Dose-dependent inhibition of cell proliferation in
MZ-CRC-1 and TT cells after 48 hours exposure. Cells
were grown in normal FCS-containing medium and
treated with increasing concentrations of imatinib for 48
hours. Cell proliferation was measured in quadruplicate
with the MTT assay. Percent proliferation inhibition was
calculated by comparison with control cell proliferation.
Results shown are representative IC50 determinations of
imatinib for RET. IC50 is obtained from the average of 4
independent experiments  SD.high, compared with the concentrations sufficientfor the inhibition of BCR-ABL and c-kit in other
cancers (Fig 8).33–42 Plasma concentrations of ima-
tinib inducing hematologic and cytogenetic re-
sponses in patients with CML were in the range of
0.17 to 5.68 mol/L. These patients were treated
with 25 to 600 mg imatinib per day.16 The maximal
achievable plasma levels of imatinib in patients are
no higher than 6.78 mol/L at maximal adminis-
tered doses of 600 mg daily. Higher doses of ima-
tinib in clinical practice are difficult to achieve,
because of adverse effects that are difficult for pa-
tients to tolerate.42 Moreover, the lethal effects of




















Fig 7. Imatinib promotes cell-cycle arrest and apoptosis.
MZ-CRC-1 cells were treated with 20 mol/L imatinib for
0, 24, 48, 72, and 96 hours. A, Annexin V/PI staining
revealed (relatively small) increasing percentages of ap-
optotic cells with increasing time of imatinib incubation.
B, Cell-cycle analysis showed increased percentages of
cells in G0/G1-phase upon longer treatment with ima-
tinib. Furthermore, the percentage of cells in S-phase
declined dramatically upon longer treatment with ima-
tinib. M1 represents G0/G1, M2 represents G2/M, and
M3 represents S-phase.imatinib on BCR-ABL expressing K562 cells are
Surgery de Groot et al 813
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lar BCR-ABL kinase activity is inhibited.13 This find-
ing suggests that a clinically relevant dose of ima-
tinib needs to inhibit at least 50% of the target
kinase activity. The IC50 of imatinib for RET is
around 4 times higher than the clinically relevant
plasma concentrations. Therefore, the plasma con-
centrations that can be achieved are not likely to
inhibit RET activity enough to be beneficial in
patients with MTC, although MTC can behave dif-
ferently in an in vivo model, and plasma levels of
imatinib do vary to a great extent among patients.
Specific inhibition of the RET-TK is a very attrac-
tive treatment option for patients with MTC. Re-
cently the kinase inhibitors ZD6474,29 CEP-701 and
CEP-751,30 and PP131,32 have been shown to inhibit
RET-TK at clinically achievable levels. ZD6474, an
inhibitor of the vascular endothelial growth factor
receptor-2, has a reported IC50 of 100 nmol/L for
RET. The indolocarbazole compounds CEP-701
and CEP-751, inhibitors of the Trk receptor ty-
rosine kinases, also have been shown to directly
inhibit RET at nanomolar levels. PP1 shows similar
IC50 (80 nmol/L) for RET, but inhibits other ki-
nases at similar or lower concentrations than RET
as well.32 None of these agents, however, has been
used in large-scale placebo-controlled trials in hu-
mans, and side effects are not yet known. Further-
more, in MTC, prolonged administration of these
inhibitors probably is necessary. It would be pref-
erable to use a tyrosine kinase inhibitor specific for
RET to minimize the potential side effects.
CONCLUSION







































































































































































Fig 8. Comparison of IC50 concentrations of imatinib in
different cancer cell lines with imatinib plasma concen-
trations. When multiple cell lines were used, the average
IC50 was used. CML, Chronic myelogenous leukemia; TC,
thyroid cancer.proliferation and RET Y1062 phosphorylation,leading to decreased RET expression in cell lines
harboring RET mutations associated with MEN 2A
and MEN 2B. The concentration of imatinib nec-
essary to inhibit RET in vitro, however, makes it
impossible to conclude at this time that imatinib
monotherapy will be a good option for systemic
therapy of MTC. In vivo studies will be necessary to
make firm conclusions concerning the clinical ap-
plication of this tyrosine kinase inhibitor as an
effective treatment for MTC.
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